Reconsidering the Trade-offs of Prostate Cancer Screening
Jonathan E. Shoag, Yaw A. Nyame, Roman Gulati, Ruth Etzioni, Jim C. Hu
Abstract
Shoag and colleagues review the long-term results of PSA screening from randomized trials and raise questions about whether the risk–benefit ratio is as strongly in favor of risk over benefit as currently gauged. The decline in PSA screening appears to have been precipitated in part by misinterpretations of data from randomized trials.
Topics & Concepts
MedicineRandomized controlled trialProstate cancer screeningProstate cancerCancer screeningProstate-specific antigenIntensive care medicineGynecologyOncologyCancerInternal medicineProstate Cancer Diagnosis and TreatmentColorectal Cancer Screening and DetectionGlobal Cancer Incidence and Screening